Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$208632.0.

  • BioNexus Gene Lab's Net Cash Flow rose 8879.63% to -$208632.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year increase of 7020.31%. This contributed to the annual value of -$1.7 million for FY2024, which is 16285.75% down from last year.
  • Per BioNexus Gene Lab's latest filing, its Net Cash Flow stood at -$208632.0 for Q3 2025, which was up 8879.63% from -$767469.0 recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Net Cash Flow ranged from a high of $4.5 million in Q3 2023 and a low of -$1.9 million during Q3 2024
  • For the 5-year period, BioNexus Gene Lab's Net Cash Flow averaged around -$59441.1, with its median value being -$188948.0 (2021).
  • Per our database at Business Quant, BioNexus Gene Lab's Net Cash Flow soared by 127854.26% in 2023 and then crashed by 1268834.63% in 2025.
  • BioNexus Gene Lab's Net Cash Flow (Quarter) stood at $401759.0 in 2021, then grew by 5.68% to $424563.0 in 2022, then crashed by 494.8% to -$1.7 million in 2023, then skyrocketed by 137.66% to $631218.0 in 2024, then tumbled by 133.05% to -$208632.0 in 2025.
  • Its Net Cash Flow stands at -$208632.0 for Q3 2025, versus -$767469.0 for Q2 2025 and -$840578.0 for Q1 2025.